FDA Loosens Reins on Crisis Lab Tests for Speed
Published Date: 9/23/2025
Notice
Summary
The FDA just released new rules about how they’ll handle certain lab tests during emergencies, like a health crisis. If you make or use these tests, this guidance explains when the FDA might relax some rules to help get tests out faster. This means quicker access to important tests without waiting for all the usual approvals, saving time and possibly money during emergencies.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA may relax rules for IVD makers
The FDA guidance explains the factors it will use to decide whether to issue an enforcement policy that allows manufacturers to offer certain unapproved in vitro diagnostic (IVD) tests or unapproved uses of approved IVD tests during a Section 564 declared emergency. If the FDA issues such an enforcement policy, makers could be allowed to provide tests without completing the usual approvals during that declared emergency.
Faster access to certain tests in emergencies
During a Section 564 declared emergency, the FDA may issue enforcement policies that allow certain unapproved IVD tests or unapproved uses of approved tests to be offered. You could get access to some lab tests sooner in that declared emergency because the guidance explains when the FDA might permit those offerings.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-18401, Multilayered Wood Flooring From the People's Republic of China: Notice of Court Decision Not in Harmony With the Results of Countervailing Duty Administrative Review; Notice of Amended Final Results
The U.S. Court of International Trade made a final decision about taxes on multilayered wood flooring from China for 2017. Because of this, the Department of Commerce is changing the subsidy rates (extra fees) for some companies like Jiangsu Senmao and Riverside Plywood, but not for Jiangsu Guyu. If you’re involved with these companies or import this flooring, expect updated fees and official changes soon.
Next: 2025-18404, Evaluation of the Georgia Coastal Management Program; Notice of Public Meeting; Request for Comments
NOAA is checking how well Georgia’s Coastal Management Program is working and wants your thoughts! If you live near Georgia’s coast or care about protecting it, now’s your chance to join a virtual meeting or send in comments. This review could shape future plans and funding to keep Georgia’s coast safe and beautiful.